blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1573048

EP1573048 - BREAST SPECIFIC PROTEIN EXPRESSED IN CANCER AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.10.2007
Database last updated on 07.10.2024
Most recent event   Tooltip11.07.2008Change - representativepublished on 13.08.2008  [2008/33]
Applicant(s)For all designated states
Avalon Pharmaceuticals, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876 / US
[2005/37]
Inventor(s)01 / WEIGLE, Bernd
Sodener, Str.9
63454 Hanau / DE
02 / RIEGER, Michael
Fiedlerstr.42
01307 Dresden / DE
03 / EBNER, Reinhard
9906 Shelburne Terrace 316
Gaithersburg, MD 20878 / US
 [2005/37]
Representative(s)Williams, Gareth Owen, et al
Marks & Clerk LLP
62-68 Hills Road
Cambridge CB2 1LA / GB
[N/P]
Former [2008/33]Williams, Gareth Owen, et al
Marks & Clerk 62-68 Hills Road
Cambridge CB2 1LA / GB
Former [2005/37]Williams, Gareth Owen, et al
Marks & Clerk 66-68 Hills Road
GB-Cambridge CB2 1LA / GB
Application number, filing date03814242.819.12.2003
[2005/37]
WO2003US40710
Priority number, dateUS20020434960P20.12.2002         Original published format: US 434960 P
[2005/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004058167
Date:15.07.2004
Language:EN
[2004/29]
Type: A2 Application without search report 
No.:EP1573048
Date:14.09.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 15.07.2004 takes the place of the publication of the European patent application.
[2005/37]
Search report(s)International search report - published on:US06.01.2005
(Supplementary) European search report - dispatched on:EP17.01.2007
ClassificationIPC:C12Q1/00, C12Q1/68, A61K39/00, A61K39/395, C07K1/00, C07K16/00, G01N33/574
[2007/07]
CPC:
C07K16/3015 (EP,US); A61K39/0011 (EP,US); A61P15/00 (EP);
A61P35/00 (EP); C12Q1/6886 (EP,US); G01N33/5011 (EP,US);
G01N33/5088 (EP,US); G01N33/57415 (EP,US); A61K2039/505 (EP,US);
C12Q2600/136 (EP,US) (-)
Former IPC [2005/37]C12Q1/00, C12Q1/68, A61K39/00, A61K39/395, C07K1/00, C07K16/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/37]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:BEI KREBS EXPRIMIERTESBRUSTSPEZIFISCHES PROTEIN UND VERFAHREN ZUR VERWENDUNG DAVON[2005/37]
English:BREAST SPECIFIC PROTEIN EXPRESSED IN CANCER AND METHODS OF USE THEREOF[2005/37]
French:PROTEINE SPECIFIQUE DU SEIN EXPRIMEE DANS LE CANCER, ET SES METHODES D'UTILISATION[2005/37]
Entry into regional phase29.06.2005National basic fee paid 
29.06.2005Search fee paid 
29.06.2005Designation fee(s) paid 
29.06.2005Examination fee paid 
Examination procedure19.07.2004Request for preliminary examination filed
International Preliminary Examining Authority: US
29.06.2005Examination requested  [2005/37]
17.04.2007Application deemed to be withdrawn, date of legal effect  [2007/45]
30.05.2007Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2007/45]
Fees paidRenewal fee
27.12.2005Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.12.200604   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO0208288  (GENENTECH INC [US], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.